Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)
NCT ID: NCT00443677
Last Updated: 2009-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
307 participants
INTERVENTIONAL
2000-04-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
NCT01251107
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
NCT00049595
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
NCT01578967
HD17 for Intermediate Stage Hodgkin Lymphoma
NCT01356680
Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL
NCT01358747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
abvd
COPPEBVCAD vs BEACOPP vs ABVD
beacopp
COPPEBVCAD vs BEACOPP vs ABVD
coppebvcad
COPPEBVCAD vs BEACOPP vs ABVD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COPPEBVCAD vs BEACOPP vs ABVD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical stage IIB, III, IV
* No prior treatment for Hodgkin disease or other malignancy
* Age 18-65 year
* Good cardiac, pulmunar, renal and hepatic function
* Performance status 0-3 (Karnofsky 100- 40)
* Written Informed Consent
Exclusion Criteria
* Large cell, anaplastic, CD30+ lymphoma
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Studio Linfomi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gruppo Italiano Studio Linfomi
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paolo Gobbi, MD
Role: PRINCIPAL_INVESTIGATOR
GISL
Emilio Iannitto, MD
Role: PRINCIPAL_INVESTIGATOR
GISL
Giuseppe Polimeno, MD
Role: PRINCIPAL_INVESTIGATOR
GISL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Oncologico Modenese
Modena, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD2000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.